Omeros | OMER - Current Liabilities


Omeros reported $85.5M in Current Liabilities for its fiscal quarter ending in June of 2025.





Current Liabilities Change Date
Adma Biologics USD 73.54M 4M Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Cytokinetics USD 199.18M 3.27M Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Immunic USD 38.36M 7.74M Mar/2026
Insmed USD 361.01M 107.87M Mar/2026
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
MacroGenics USD 95.94M 52.82M Mar/2026
Omeros USD 85.5M 2.28M Jun/2025
Pacira USD 108.79M 11.8M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Rockwell Medical USD 10.95M 259K Jun/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
United Therapeutics USD 599.1M 38.5M Mar/2026
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026
Xoma USD 28.3M 6.81M Sep/2025